Delivering an effective therapeutic payload to specific target cells with few adverse effects is considered by many to be the ‘holy grail’ of medical research.
A new study carried out at Tel Aviv University has explored a biological approach to directing nanocarriers loaded with protein “game changers” to specific cells.
Researchers say the groundbreaking method may prove useful in treating myriad malignancies, inflammatory diseases and rare genetic disorders.
Prof. Dan Peer, director of the Laboratory of Precision Nanomedicine at the School of Molecular Cell Biology at TAU’s Faculty of Life Sciences, led the research for the new study, which was conducted by TAU graduate student Nuphar Veiga and lab colleagues Meir Goldsmith, Yasmin Granot, Daniel Rosenblum, Niels Dammes, Ranit Kedmi and Srinivas Ramishetti. The research was published in Nature Communications.
Over the past few years, lipid carriers encapsulating messenger RNAs (mRNAs) have been shown to be extremely useful in altering the protein expressions for a host of diseases. But directing this information to specific cells has remained a major challenge.
“In our new research, we utilized mRNA-loaded carriers — nanovehicles carrying a set of genetic instructions via a biological platform called ASSET — to target the genetic instructions of an anti-inflammatory protein in immune cells,” says Peer.
“We were able to demonstrate that selective anti-inflammatory protein in the target cells resulted in reduced symptoms and disease severity in colitis.
“This research is revolutionary. It paves the way for the introduction of an mRNA that could encode any protein lacking in cells, with direct applications for genetic, inflammatory and autoimmune diseases — not to mention cancer, in which certain genes overexpress themselves.”
ASSET (Anchored Secondary scFv Enabling Targeting) uses a biological approach to direct nanocarriers into specific cells to promote gene manipulation.
“This study opens new avenues in cell-specific delivery of mRNA molecules and ultimately might introduce the specific anti-inflammatory (interleukin 10) mRNA as a novel therapeutic modality for inflammatory bowel diseases,” says Veiga.
“Targeted mRNA-based protein production has both therapeutic and research applications,” she concludes.
“Going forward, we intend to utilize targeted mRNA delivery for the investigation of novel therapeutics treating inflammation disorders, cancer and rare genetic diseases.”